Singlera Genomics has raised $150 million in series B financing to expand the company's early cancer screening research and development pipeline. The funds will also be used to promote product registration and commercialization and to expand prospective studies into pan-cancer early screening.
The financing was led by the CICC Kai Tak Innovative Biomedicine Fund and co-led by Detong Capital and Furong Investment. Other investors include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures.
Singlera's next priority is to accelerate the commercialization of its products.
